TY - JOUR
T1 - Factors associated with using opiates while under extended-release naltrexone blockade
T2 - A descriptive pilot study
AU - Jarvis, Brantley P.
AU - DeFulio, Anthony
AU - Long, Lauren
AU - Holtyn, August F.
AU - Umbricht, Annie
AU - Fingerhood, Michael
AU - Bigelow, George E.
AU - Silverman, Kenneth
N1 - Funding Information:
This work was supported by the National Institute on Drug Abuse of the National Institutes of Health ( R01DA019497 and T32DA07209 ). Alkermes, Inc. supplied the medication (Vivitrol®) at no cost for the main trial. Neither Alkermes, Inc. or the National Institutes of Health had any further role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/2
Y1 - 2018/2
N2 - Background and aim Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4 weeks, yet many patients continue to use them. To learn more about why this occurs, we collected self-reports on subjective effects and drug use factors from participants’ most recent heroin/opiate use while under XR-NTX blockade. Methods Participants (n = 38) were unemployed, heroin-dependent adults enrolled in a randomized controlled trial evaluating employment-based incentives to promote adherence to XR-NTX. A subset of participants (n = 18) were asked to complete a survey about their most recent use of heroin/opiates when they provided an opiate-positive urine sample while under XR-NTX blockade. Surveys were administered weekly, and participants could complete multiple surveys throughout the trial. Participants reported how high they were (11-point scale; 0 = not at all, 10 = extremely), how much heroin/opiates they took (less, more, or about the same as usual before starting naltrexone), whether they used cocaine at the same time, and the routes of administration for heroin/opiates and cocaine (if used). All analyses were descriptive. Results Of the 107 surveys, 75.7% indicated being “not at all” high the last time heroin/opiates were used. 75.5% of surveys reported opiate amounts that were less than usual, and only 7.5% reported amounts larger than usual. Cocaine was used at the same time as heroin for 57.9% of surveys but typically through a different route (74.2%). Discussion Using heroin/opiates while under XR-NTX blockade is not strongly associated with self-reports of high, taking larger than normal amounts of opiates, or taking opiates and cocaine simultaneously via the same route. Future research should incorporate measures of naltrexone concentration and more comprehensive and frequent assessments using ecological momentary assessment.
AB - Background and aim Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4 weeks, yet many patients continue to use them. To learn more about why this occurs, we collected self-reports on subjective effects and drug use factors from participants’ most recent heroin/opiate use while under XR-NTX blockade. Methods Participants (n = 38) were unemployed, heroin-dependent adults enrolled in a randomized controlled trial evaluating employment-based incentives to promote adherence to XR-NTX. A subset of participants (n = 18) were asked to complete a survey about their most recent use of heroin/opiates when they provided an opiate-positive urine sample while under XR-NTX blockade. Surveys were administered weekly, and participants could complete multiple surveys throughout the trial. Participants reported how high they were (11-point scale; 0 = not at all, 10 = extremely), how much heroin/opiates they took (less, more, or about the same as usual before starting naltrexone), whether they used cocaine at the same time, and the routes of administration for heroin/opiates and cocaine (if used). All analyses were descriptive. Results Of the 107 surveys, 75.7% indicated being “not at all” high the last time heroin/opiates were used. 75.5% of surveys reported opiate amounts that were less than usual, and only 7.5% reported amounts larger than usual. Cocaine was used at the same time as heroin for 57.9% of surveys but typically through a different route (74.2%). Discussion Using heroin/opiates while under XR-NTX blockade is not strongly associated with self-reports of high, taking larger than normal amounts of opiates, or taking opiates and cocaine simultaneously via the same route. Future research should incorporate measures of naltrexone concentration and more comprehensive and frequent assessments using ecological momentary assessment.
KW - Blockade
KW - Challenge
KW - Extended-release naltrexone
KW - Heroin
KW - Opioids
UR - http://www.scopus.com/inward/record.url?scp=85011271321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011271321&partnerID=8YFLogxK
U2 - 10.1016/j.jsat.2016.12.006
DO - 10.1016/j.jsat.2016.12.006
M3 - Article
C2 - 28161142
AN - SCOPUS:85011271321
SN - 0740-5472
VL - 85
SP - 56
EP - 60
JO - Journal of Substance Abuse Treatment
JF - Journal of Substance Abuse Treatment
ER -